Back to results
US 10,329,346 B2Granted
TNFa-IL-17 bispecific antibodies
AssigneeHoffmann-La Roche Inc.
InventorsJohannes Auer, Martin Bader, Jens Fischer, Stefan Lorenz, Joerg Moelleken, Stefan Seeber
Life of this patent
Estimating the term…
Abstract
Bispecific tetravalent antibodies against IL-17 and TNFa, useful in therapy, e.g. the treatment of rheumatoid arthritis and other autoimmune diseases and/or to reduce pathological inflammatory conditions.
Claims23
A bispecific tetravalent antibody against IL-17 and TNFa, the antibody comprising two heavy chains, two first soluble chains, and two second soluble chains,
- wherein each heavy chain comprises, from N-terminus to C-terminus:
- a first VH domain,
- a CH1 domain,
- a CH2 domain,
- a CH3 domain, and either
- (i) a second VL domain and a CH1 domain, or
- (ii) a second VH domain and a CL domain and;
- wherein the two first soluble chains each comprise, from N-terminus to C-terminus, a first VL domain and a first CL domain, and wherein the two second soluble chains each comprise, from N-terminus to C-terminus, either
- (i) a second VL domain and a CH1 domain, or
- (ii) a second VH domain and a CL domain;
- wherein each of the first soluble chains is associated with a respective heavy chain to provide a first antigen-binding site comprising a first VH domain and a first VL domain, thereby providing two first antigen-binding sites, and each of the second soluble chains is associated with a respective heavy chain to provide a second antigen-binding site comprising a second VH domain and a second VL domain, thereby providing two second antigen-binding sites;
- and
- wherein either (i) each first antigen-binding site is an IL-17 binding site and each second antigen-binding site is a TNFa binding site;
- or (ii) each first antigen-binding site is a TNFa binding site and each second antigen-binding site is an IL-17 binding site, wherein:
- a) each binding site against IL-17 comprises a VH domain and a VL domain, wherein the VH domain comprises CDRH1 of SEQ ID NO:
- 1, CDRH2 of SEQ ID NO:
- 2, and CDRH3 of SEQ ID NO:
- 3, and wherein the VL domain comprises CDRL1 of SEQ ID NO:4, CDRL2 of SEQ ID NO:
- 5, and CDRL3 of SEQ ID NO:6;
- and
- b) each binding site against TNFa comprises a VH domain and a VL domain, wherein the VH domain comprises CDRH1 of SEQ ID NO:
- 31, CDRH2 of SEQ ID NO:
- 32, and CDRH3 of SEQ ID NO:
- 33, and wherein the VL domain CDRL1 of SEQ ID NO:34, CDRL2 of SEQ ID NO:
- 35, and CDRL3 of SEQ ID NO:
- 36.
23 more elements
Dependencies are inferred from the claim text.